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Background: Advanced or recurrent nonresectable thymic epithe-
lial tumors show only a modest response to standard chemotherapy.
A recent study using octreotide and prednisone in thymic tumors,
Eastern Cooperative Oncology Group study E1C97, was conducted
to verify the activity of octreotide for thymic tumors. The aim of this
study was to determine whether epidermal growth factor receptor
(EGFR) immunoreactivity correlated with outcomes and to identify
new biologic markers for potential targeted therapy. Three markers,
EGFR, C-kit, and Her2/neu, were selected for evaluation in patients
with advanced thymic epithelial tumors treated on E1C97.
Methods: Of the 42 patients entered onto E1C97, 34 patients
(World Health Organization WHO categories: type A  1, type
AB  1, type B1  10, type B2  11 type B3  8, and type C 
3) had sufficient tissue available for immunohistologic study.
Each tumor was assessed to have 0, 1, 2, or 3 immunore-
activity in the cytoplasm or membranes of the neoplastic cells for
Her2/neu and EGFR and for the presence or absence of C-kit
immunoreactivity.
Results: EGFR immunoreactivity of 2 or 3 was associated
with more aggressive thymic tumors (WHO types B2 and B3).
However, strong EGFR immunoreactivity was not consistently
seen with thymic carcinoma. The presence of EGFR within cells
was associated with a significantly improved progression-free
survival (PFS) and a trend for overall survival (OS). Twelve
patients demonstrated C-kit immunoreactivity; the lack of C-kit
immunoreactivity was significantly associated with superior PFS
but not OS. Her2/neu immunoreactivity was uniformly negative
for all tumors evaluated. There was no association between
response and biomarker status.
Conclusions: High EGFR immunoreactivity is seen in more aggres-
sive thymic neoplasms as classified according to the 2004 WHO, but
regardless of classification, the presence of EGFR in tumor cells
(1, 2, and 3) is associated with improved performance free
survival (PFS) and a trend for better OS. In contrast, the absence of
C-kit immunoreactivity was associated with improved PFS. These
data suggest that EGFR and C-kit may be prognostic, and further
studies of these markers in subcategories of thymic malignancies is
warranted.
Key Words: Thymoma, 2004 WHO classification of thymoma,
Octreotide, Thymic epithelial neoplasms, EGFR, C-kit, Her2/neu.
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Thymoma and thymic carcinoma are rare anterior medi-astinal tumors derived from thymic epithelium, which
contain varying proportions of nonneoplastic lymphocytes.
Thymomas encompass a wide variety of histologic patterns
that are associated with diverse outcomes. In recent years,
several classification systems, including those proposed by
Marino and Muller-Hermelink,1 Masoaka et al.,2 and Sus-
ter and Moran3 have been developed in an attempt to
categorize these heterogeneous tumors to predict prognosis
and therapeutic options. In the 2004 World Health Orga-
nization (WHO) classification,4 thymomas are classified
according to their cytologic appearance and also in asso-
ciation with the relative number of nonneoplastic lympho-
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cytes present. There is currently no single classification
system in use worldwide. However, tumor stage remains
the single most important prognostic factor in determining
patient outcome.
The primary mode of therapy for thymomas is surgical
extirpation. However, when the tumor demonstrates invasion
of the capsule or invades into adjacent mediastinal structures
or lung parenchyma, the prognosis worsens, and additional
modes of therapy such as radiotherapy or chemotherapy are
typically used. Although chemotherapy has a broad range of
activity, it does not appear curative in patients with unresect-
able disease. Thus, newer therapies, such as molecular tar-
geted agents alone or in combination with other agents may
be useful in treating advanced thymic malignancies.
A case report using octreotide plus prednisone pro-
duced a complete response in a patient with thymoma and
pure red cell aplasia.5 Based on this report, a prospective trial
evaluating octreotide plus prednisone (Eastern Cooperative
Oncology Group ECOG E1C97: A phase II study of oct-
reotide treatment of advanced, recurrent thymoma) was con-
ducted in patients with thymoma whose pretreatment oct-
reotide scans were positive. We subsequently performed a
correlative study on tissue obtained from patients entered on
this trial. We assessed the immunohistochemical expression
of epidermal growth factor receptor (EGFR), C-kit, and
TABLE 1. Baseline Patient Demographics and Disease
Characteristics
Total
n  34 Percentage
Age, median (range) 50 (31–71)
Performance status
0 21 62
1 13 38
Sex
Male 16 47
Female 18 53
Race
White 27 79
Black 3 9
Other 4 12
Weight loss previous 6 mo
5% 30 91
5% 3 9
Group
Octreotide 14 41
Octreotide  prednisone 20 59
C-kit
Low 21 88
High 3 13
EGFR
Negative 8 24
Positive 26 76
Her2-neu
Negative 0 100
Regional lymph node involvement
No 20 61
Yes 13 39
Chronic disease
No 15 44
Yes 19 56
Chronic medications
No 11 32
Yes 23 68
Histology
Thymoma 29 85
Thymic carcinoid 1 3
Other 4 12
Prior paraneoplastic
No 31 91
Yes 3 9
Prior malignancies
No 31 91
Yes 3 9
Previous surgery
No 3 9
Yes, biopsy only 4 12
Yes 27 79
Previous radiotherapy
No 6 18
Yes, primary 19 56
Yes, metastatic 5 15
Yes, both 4 13
Total
n  34 Percentage
Prior chemo, no. of regimens
None 7 21
1 15 44
2 8 24
3 4 13
Metastatic sites
Lung 20 59
Pleura 20 59
Liver 5 15
Bone marrow 2 6
Bone 2 6
Subcutaneous 1 3
Other 11 32
Stage
III 2 11
IV 15 39
Missing 17 50
WHO
A 1 3
AB 1 3
B1 10 29
B2 11 32
B3 8 24
C 3 9
CD5
0 27 96
Positive 1 4
EGFR, epidermal growth factor receptor; WHO, World Health Organization.
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Her2/neu and correlated the immunohistochemical expres-
sion of these three markers with PFS and overall survival
(OS) in this group of 34 patients with invasive, recurrent, or
metastatic thymoma.
PATIENTS AND METHODS
Of the 42 patients entered onto ECOG trial E1C97 of
octreotide treatment in advanced, recurrent thymoma, paraf-
fin-embedded tumor tissue from thymic resection or biopsy
was available for 36 patients in the study group. Two patients
were deemed ineligible and removed from the study. Among
the 34 patients included in this correlative study, there were
18 female and 16 male patients with a median age of 50.5
years and a range of 31.0 to 70.5 years.
Hematoxylin and eosin stained slides were reviewed
on all submitted cases on tumor specimens obtained at the
time of initial diagnosis. All cases were classified accord-
ing to the 2004 WHO classification of thymic epithelial
neoplasms.4 Five-micrometer sections of formalin-fixed,
paraffin-embedded tissue tumor was used for immunohis-
tochemical staining for EGFR, C-kit, and Her2/neu expres-
sion. Two of the authors (S.C.A. and M.R.H.) each re-
viewed all the immunohistochemical stains and the control
slides. Slides for EGFR immunostaining were deparaf-
finized and treated with hydrogen peroxide for 5 minutes at
room temperature. Then they were treated with protein-
ase-k at room temperature for 5 minutes. The slides were
then incubated with antibodies against EGFR for 30 min-
utes (DAKO, Carpinteria, CA, mouse monoclonal anti-
body H11). The detection system used was the Envision 
Mouse (DAKO) EGFR, a tyrosine kinase growth factor
receptor stains in a similar pattern to Her2/neu. Staining
for EGFR was interpreted as 0 (negative) to 3 (strong
membrane staining) based on standardized criteria as used
for Her/2-neu to evaluate tumor positivity in breast cancer6
and the previous work on EGFR expression in invasive
thymoma by Henley et al.7
Slides prepared for C-kit immunostaining were depar-
affinized and pretreated with Trilogy (Cell Marque, Rocklin,
CA, rabbit monoclonal antibody YR 145) in a steamer for 60
minutes. They were then treated with hydrogen peroxide for
5 minutes at room temperature, after which the slides were
then incubated with antibodies to C-kit for 60 minutes. The
detection system used was the Envision  Mouse (DAKO).
Membrane and cytoplasmic staining for C-kit positivity was
interpreted as either positive or negative.
Slides for Her2/neu immunostaining were deparaf-
finized and prepared as per instructions for the Hercep Test
(DAKO Cytomation, Carpinteria, CA). Positive and negative
control slides including membrane staining of 0, 1, and 3
were used for all runs. The stained slides were evaluated for
membrane positivity and scored according to the standards
currently used for Her2/neu staining on invasive breast cancer
cells. CD5 was performed on all cases and was positive in
only one of five thymic carcinoma cases classified by the
WHO classification method.
FIGURE 1. Progression-free sur-
vival by epidermal growth factor
receptor (EGFR) group.
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Statistical Methods
EGFR was categorized as negative (0) or positive (1,
2, or 3), and C-kit was categorized as low (0 or 1)
versus high (2 or 3). Differences in response measured
per RECIST criteria were tested with Fisher’s exact test.
Progression-free survival (PFS) was defined as the time from
randomization to progression or death, whichever occurred
first. OS was defined as the time from registration to date
of death from any cause. Patients not experiencing an
event were censored at the last date of follow-up. The
Kaplan-Meier method was used to estimate the distribution
of event-time distributions. Univariate associations be-
tween demographic variables and immunomarker groups
and time-to-event endpoints were assessed with Cox pro-
portional hazards models, and variables significant at the
0.10 level were included in stepwise multivariate regres-
sion models. All tests conducted were two sided at a 0.05
significance level. There were no adjustments made for
multiple comparisons.
RESULTS
Baseline demographics and disease characteristics
are summarized in Table 1, as are the staining results for
EGFR, C-kit, and Her2/neu. The median time from diag-
nosis to registration to the study was 46.57 days. The
median age of these patients was 50 years (range 31–71
years), and 38% of the patients had performance status 1 at
the time of study entry. Fifty-three percent of patients were
women, and 91% of patients experienced less than 5%
weight loss in the 6 months before registration. Seventy-
six percent of patients had tumors that were EGFR posi-
tive, and 88% of patients had tumors that measured low or
no C-kit positivity. The majority of patients with WHO B
subtype demonstrated EGFR positivity (24/29  83%).
The breakdown of subclassification of the positive EGFR
staining in WHO B subtype is as follows: B1 8 of 10, B2
9 of 11, and B3 7 of 8. EGFR immunoreactivity was noted
in only one of five patients with thymic carcinoma. EGFR
immunoreactivity was not seen in the one patient with AB
histologic subtype.
C-kit immunoreactivity was considered positive with
the presence of either cytoplasmic or membrane staining and
was noted in 11 of 29 patients with B histologic subtype
(38%) with C-kit positivity noted as follows: B1 4 of 10, B2
5 of 11, and B3 2 of 8. C-kit immunoreactivity was noted in
only one of five patients with thymic carcinoma. C-kit im-
munoreactivity was not noted in the one patient with AB
histologic subtype. Her2/neu immunoreactivity was uni-
formly negative in all tumor tissues examined.
PFS (Figure 1) was significantly higher among those
with EGFR positivity (11.2 months 8.5–20.0 months
versus 3.7 months 1.9-Inf mos, log-rank test p  0.001).
Patients with high C-kit expression had an inferior PFS
then those with low C-kit expression (Figure 2). Despite
the small numbers, those without C-kit expression had a
superior PFS (median 9.5 months 6.1–14.9 months) com-
FIGURE 2. Progression-free sur-
vival by C-Kit group.
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pared with those with C-kit expression (median 1.9 months
1.8-Inf; log-rank test p  0.004).
The results of the univariate analyses of predictors of
PFS are presented in Table 2. Performance status, presence of
liver metastases, EGFR status, and C-kit status were the
variables that were included in the multivariate model, from
which performance status was ultimately omitted. After ad-
justing for the presence of liver metastasis, EGFR positivity
(hazard ratio  0.16, 95% confidence interval: 0.06–0.43,
p  0.0004) and low C-kit expression (hazard ratio  0.08,
95% confidence interval: 0.02–0.35, p  0.0008) remained
significant predictors of PFS.
OS (Figure 3) for patients with EGFR positivity (me-
dian 64.3 months 43.4–93.3 months) tended to be better
than that of patients without EGFR expression (median 39.9
months 15.2-Inf mos, log-rank test p value 0.058). Those
with high C-kit expression tended toward an inferior OS, but
the difference was not statistically significant (log-rank test
p  0.12). The median OS (Figure 4) for patients with high
C-kit expression was 34.6 months (16.0-Inf) compared with
63.6 months (43.4–88.0 months) for those with low expres-
sion. Regional lymph node involvement, presence of liver
metastases, histology, and EGFR expression were univariate
predictors of OS at the 0.10 level, but EGFR failed to remain
significant in a multivariate model.
With respect to the best overall response of complete
or partial response, there was no association betw-
een response and either EGFR or C-kit immunoreactivity
(Table 3).
DISCUSSION
Thymomas are classified histologically by their varied
mixture of neoplastic epithelial cells and benign lympho-
cytes, with type A being pure spindle epithelial cells, type AB
demonstrating a mixture of spindle cells and lymphocytes,
type B1–B3 representing varied mixtures of lymphocytes and
neoplastic epithelial cells, and type C representing overt
thymic carcinoma.4 The stage of the disease is determined
independently by the degree of tumor invasiveness and pres-
ence of metastasis.8 During the past several decades, a num-
ber of classification systems evolved, including those pro-
posed by Marino and Muller-Hermelink,1 Masaoka et al.,2
and Suster and Moran3 and WHO4 in an attempt to categorize
these heterogeneous tumors to predict prognosis and thera-
peutic options. Although the Muller-Hermelink, Suster-
Moran, and WHO classification schema are predominantly
based on cytologic atypia and on the relative ratio of neo-
plastic epithelial thymocytes to lymphocytes, the Masaoka
system predominantly focuses on the presences of capsular
TABLE 2. Univariate Cox Model Results for Overall Survival and Progression-Free Survival
OS PFS
HR 95% CI p HR 95% CI p
Group (octreotide vs. oct.  prednisone) 1.63 0.78–3.44 0.2 1.89 0.92–3.85 0.8
Performance status (1 vs. 0) 3.91 1.67–9.14 0.002 2.01 0.97–4.17 0.06
Age 1.01 0.98–1.05 0.54 1.01 0.98–1.05 0.48
Sex (male: female) 1.3 0.61–2.75 0.5 1.17 0.58–2.39 0.66
Regional lymph node involvement 3.2 1.36–7.53 0.008 2.01 0.97–4.2 0.06
Lung mets 0.67 0.32–1.42 0.3 1.16 0.57–2.39 0.68
Pleura mets 1.23 0.56–2.69 0.6 0.88 0.43–1.83 0.74
Liver mets 4.48 1.56–12.92 0.005 2.86 1.06–7.75 0.04
Bone marrow mets 0.58 0.08–4.32 0.59 1.02 0.24–4.31 0.98
Bone mets 1.22 0.28–5.24 0.79 1.19 0.28–5.06 0.81
Subcutaneous mets 1.03 0.24–4.4 0.97 1.07 0.25–4.56 0.92
Other mets 1.34 0.6–2.99 0.48 1.3 0.6–2.78 0.51
Weight loss previous 6 mo 5% 0.54 0.12–2.36 0.41 0.65 0.15–2.75 0.55
Time (days) from diagnosis to registration 46.57 (median) 1.38 0.64–2.96 0.41 1.58 0.77–3.25 0.21
Chronic diseases present 0.87 0.41–1.88 0.73 0.99 0.48–2.01 0.97
Chronic medications administered 0.96 0.43–2.14 0.92 1.04 0.49–2.22 0.91
Histology (thymoma/thymic carcinoid vs. other) 0.25 0.08–0.8 0.02 1.05 0.92–1.2 0.45
Prior paraneoplastic syndromes 0.71 0.17–2.99 0.63 0.46 0.11–1.93 0.29
Prior malignancies 1.75 0.52–5.9 0.37 1.07 0.32–3.59 0.91
Previous surgery 0.68 0.39–1.18 0.17 0.88 0.53–1.44 0.6
Previous radiotherapy 1.18 0.44–3.14 0.75 1.62 0.62–4.24 0.33
Previous systemic therapy 1.25 0.83–1.89 0.28 1 0.69–1.44 1
Number of prior chemotherapy regimens 0.78 0.44–1.39 0.4 0.95 0.55–1.67 0.87
Stage 1.2 0.28–5.15 0.81 1.85 0.42–8.05 0.41
EGFR (positive vs. negative) 0.45 0.19–1.05 0.07 0.25 0.1–0.62 0.003
C-kit (low vs. high) 0.38 0.11–1.33 0.13 0.17 0.04–0.63 0.008
OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; EGFR, epidermal growth factor receptor.
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invasion or gross involvement of mediastinal structures.
There is currently no single classification system in use
worldwide. However, the 2004 WHO classification on thymic
epithelial neoplasms chaired by Muller-Hermelink et al.4 is
one of the more commonly used histologic classification.
Detterbeck,9 Rena et al.,10and Strobel et al.,11 have validated
the usefulness of the WHO histologic classification of thymic
epithelial neoplasms for predicting patient outcomes.
Immunohistochemical staining has become the stan-
dard of care in diagnosing and classifying patients for
treatment in certain other malignancies. For example, C-kit
immunoreactivity is used for classifying certain neoplasms
as gastrointestinal stromal tumor. Identifying this marker
helped to find agents for potential therapy, and today a
reasonable percentage of these patients with gastrointesti-
nal stromal tumor will experience significant and enduring
tumor responses to imatinib, a C-kit inhibitor. Immunohis-
tochemistry for thymomas has so far not contributed to any
classification system or the identification of specific treat-
ment targets.
Our study confirms other reports demonstrating a high
percentage of EGFR positivity in thymic epithelial tu-
mors.6,11,12–15 EGFR mutations have been rarely reported in
thymic tumors.13,14,16.
EGFR, is a member of the Erb family of receptors
consisting of an extracellular ligand-binding domain, a
transmembrane domain, and an intracellular cytoplasmic
domain with tyrosine kinase activity17 and is activated on
ligand binding. It is expressed in most normal epithelial
cells but not in mature hematopoietic cells.17 Malignant
transformation can result due to deregulation of these
tightly controlled signaling pathways. More than one third
of solid tumors express EGFR as measured by immuno-
histochemical analysis. Often these tumors present at an
advanced stage.18 EGFR is expressed in a wide variety of
tumors18 including head and neck, colorectal, lung, pan-
creatic, esophagus, kidney, prostate, bladder, cervix,
ovary, and breast. Multiple clinical trials are now under-
way targeting EGFR with anti-EGFR agents either as
monotherapy or in combination with standard chemother-
apy, radiation therapy, or other targeted agents.18
Our ECOG study afforded the opportunity to correlate
EGFR, C-kit, and Her2/neu expression with clinical outcome
data including response, PFS, and OS in a population which
received uniform salvage therapy with octreotide with or
without prednisone. Our results demonstrate that the presence
of EGFR immunostaining in tumor cells (1, 2, and 3) was
associated with a significantly better PFS with a trend toward
improved OS. In addition, the presence of C-kit immunore-
activity was associated with a significantly worse PFS. How-
ever, we could not demonstrate any association with response
to octreotide.
A limitation of this study is the small sample size
including a small number of patients with high C-kit and low
FIGURE 3. Overall survival by epi-
dermal growth factor receptor
(EGFR) group.
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EGFR positivity. In addition, all patients registered had
advanced, recurrent, or unresectable disease (stage III/IV)
and showed tumor uptake with radionuclide octreotide. The
inclusion of patients with only octreotide scan positive dis-
ease may also have an uncertain impact on the association of
these markers, and this needs to be confirmed in other series.
Another potential impact on the differences in PFS and OS
for these markers is that postprotocol treatments were not
controlled.
This study suggests that immunohistochemical stain-
ing for EGFR and C-kit may have prognostic potential.
However, the role of these markers and their mutations as
predictors of targeted therapeutics is unclear. Case reports
of activity with cetuximab and imatinib in patients with
thymoma and thymic carcinoma have been published.19,20
Other phase II trials with imatinib and gefitinib have failed
to demonstrate significant clinical activity,20–23 as did
another trial using erlotinib plus bevacizumab.24 Further
studies are needed to define the frequency of mutations on
these markers, whether such mutations carry therapeutic
predictive capabilities, and the importance of these path-
ways on carcinogenesis and drug resistance.
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TABLE 3. Association between Best Overall Response and EGFR and C-kit Status
EGFR
p
C-kit
p
TotalNegative Positive Low High
n  34 Percentagen  8 Percentage n  26 Percentage n  31 Percentage n  3 Percentage
Response
SD, PD 7 88 16 62 20 65 3 100 23 68
CR, PR 1 13 10 38 0.23 11 35 0 0 0.53 11 32
EGFR, epidermal growth factor receptor; SD, stable disease; PD, progressive disease; CR, complete response; PR, partial response.
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